LAUSR

23R and IL-17A and novel insights into their associations with inflammatory bowel disease. Gut 2011; 60:1527–36. https://doi. org/10.1136/gut.2011.238477. 7 Catana CS, Berindan Neagoe I, Cozma V et al. Contribution of the IL-17/IL-23 axis to the pathogenesis of inflammatory bowel disease. World J Gastroenterol 2015; 21:5823–30. https://doi.org/10. 3748/wjg.v21.i19.5823. 8 Elmets CA, Leonardi CL, Davis DMR et al. Joint AAD–NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol 2019; 80:1073–113. https://doi.org/10.1016/j.jaad.2018.11.058. 9 Garg A, Malviya N, Strunk A et al. Comorbidity screening in hidradenitis suppurativa: evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations. J Am Acad Dermatol 2022; 86:1092–101. https://doi.org/10.1016/j.jaad. 2021.01.059. 10 Fauny M, Moulin D, D’Amico F et al. Paradoxical gastrointestinal effects of interleukin-17 blockers. Ann Rheum Dis 2020; 79:1132–8. https://doi.org/10.1136/annrheumdis-2020-217927.